Regarding the Appointment of Life Medical Science Advisors and Sub – Advisors

           

2025.11.17

A portion of our innovative technology was presented at the nationwide conference of the Japanese Society of Laboratory Medicine in August 2025. Furthermore, in September 2025, we commenced the release of the Android-based application “FLD HbA1c.”

Additionally, on October 22, 2025, we began releasing the “FLD HbA1c” app in seven countries across Southeast and Southwest Asia. Next year, we aim to present at academic conferences with a focus on non-contact and non-invasive measurement methods for new parameters, such as “LDL Cholesterol.”

In light of these developments, we are pleased to announce the establishment of positions for a Biomedical Science Advisor and a Sub-Advisor. The purpose of appointing these advisors is to accelerate the innovation of our future technologies by reinforcing cutting-edge medical insights.

The Biomedical Science Advisor and Sub-Advisor will be involved in the development and research of new fields related to our future-oriented advanced technologies. We are currently in the process of bringing on board promising researchers from the University of Tokyo, who have had their work published in highly esteemed international academic journals, as well as researchers with global achievements. Upon securing their consent, we will provide further updates regarding their accomplishments and contributions.

• prev